We are proud to share with you that, Orgenesis Inc., (ORGS), a manufacturer, service provider and developer of advanced cell therapies, announced that its common stock has been approved for listing on the NASDAQ Capital Market (“NASDAQ”). Trading on NASDAQ is expected to commence on March 13, 2018 under the current trading symbol, ORGS.
Mark Cohen, Senior Partner and Chair of the Life Science Practice Group represents Orgenesis in its corporate, commercial, and intellectual property matters.
CLICK HERE to read more.
